Trial Information
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
The blood sample will be used in the laboratory to perform focused studies on Chronic
Lymphocytic Leukemia (CLL).
Inclusion Criteria:
- Patients undergoing routine blood draws as part of their ongoing follow-up care for
CLL at the Norris Cotton Cancer Center of DHMC.
- Normal donors who have no history of active or prior hematologic malignancy.
Exclusion Criteria:
- Patients who have received cytotoxic drug, oral or intravenous steroid or targeted
antibody therapy for their CLL, other hematologic malignancy or other disease process
within the past 2 months are excluded. Use of intravenous immunoglobulin (IVIg) is
not a reason for exclusion.
- Normal donors who have a history of steroid use, immunosuppression therapy or
autoimmune disease are excluded.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To identify the genes that are differentially expressed at the polysomal RNA and protein levels in human patient CLL cells (compared to normal donor lymphocytes) using high-throughput microarray approaches.
Outcome Time Frame:
2 Years
Safety Issue:
No
Principal Investigator
Christopher H Lowrey, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Dartmouth-Hitchcock Medical Center
Authority:
United States: Institutional Review Board
Study ID:
D1019
NCT ID:
NCT01069432
Start Date:
May 2010
Completion Date:
February 2011
Related Keywords:
- Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- CLL
- Normal Volunteers
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
Name | Location |
Dartmouth-Hitchcock Medical Center |
Lebanon, New Hampshire 03756 |